NXT2B

Navinci Diagnostics AB is a biotechnology company based in Uppsala, Sweden, specializing in biomolecular analysis for cancer and prenatal diagnostics. The company focuses on developing proprietary technology that facilitates the detection and quantification of proteins, their interactions, and modifications in various sample types, including tissue, cells, and blood. Navinci Diagnostics offers a range of products, including universal kits that can analyze cultured cells, fresh-frozen, and formalin-fixed paraffin-embedded (FFPE) samples, as well as target-specific kits that are pre-optimized for specific variables. Additionally, the company provides in-house immunostaining and custom assay services to enhance research and diagnostic capabilities.

Vivolux AB is a Swedish biopharmaceutical company established in 2006, headquartered in Mölndal. It specializes in cancer drug discovery, development, and manufacturing. Vivolux's innovative approach combines cutting-edge expertise in molecular biology with an open-minded pursuit of new possibilities. The company focuses on mechanistic studies to create novel anticancer drugs like VLX600, an iron chelator inducing tumor cell death, and VLX1570, a proteasome inhibitor triggering apoptosis. Its platform employs advanced culture systems for drug screening and optimization, aiming to provide lifesaving tools for cancer treatment.